$0.00
(0.00%
) Quote detailsUSD
$0.00
(0.00%
)At Close (As of Dec 9, 2025)
$12.91B
Market Cap
-
P/E Ratio
-12.91
EPS
$605.00
52 Week High
$265.00
52 Week Low
HEALTHCARE
Sector
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in West Conshohocken, Pennsylvania, focused on developing innovative therapies for cardiovascular, metabolic, and liver diseases. Its lead product candidate, resmetirom, is aimed at treating non-alcoholic steatohepatitis (NASH), addressing a significant unmet medical need in an underserved patient population. With a robust pipeline and promising clinical trial results, Madrigal is positioned as a key player in the metabolic disease sector, presenting a compelling investment opportunity for institutional investors seeking to support advancements in health solutions.
LPTX
NVDA
WBD
ASST
VHAI
PLUG
BYND
AAL
TSLA
INTC
SOFI
CFLT
NFLX
ADAP
GRAB
BITF
BAC
PFE
MARA
T
DNN
KVUE
IRBT
WULF
CIFR
F
CLSK
KEY
VZ
APLD
HPE
RGTI
CXAI
IREN
GOOGL
HBAN
NIO
BTBT
MTSR
DVLT
RIG
AMD
RR
SOUN
MSTR
XOM
AVGO
SNAP
WMT
MRVL
VALE
QBTS
KDP
CAN
ITUB
SLM
NVTS
AGNC
NCLH
HOOD
PCG
LPTX
NVDA
WBD
ASST
VHAI
PLUG
BYND
AAL
TSLA
INTC
SOFI
CFLT
NFLX
ADAP
GRAB
BITF
BAC
PFE
MARA
T
DNN
KVUE
IRBT
WULF
CIFR
F
CLSK
KEY
VZ
APLD
HPE
RGTI
CXAI
IREN
GOOGL
HBAN
NIO
BTBT
MTSR
DVLT
RIG
AMD
RR
SOUN
MSTR
XOM
AVGO
SNAP
WMT
MRVL
VALE
QBTS
KDP
CAN
ITUB
SLM
NVTS
AGNC
NCLH
HOOD
PCG